Loading…
Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy
Background: SGI-110 (guadecitabine) is a novel HMA that prolongs in vivo exposure of the active moiety decitabine following subcutaneous (SC) administration. We previously reported guadecitabine clinical activity in previously untreated elderly AML with Overall Complete Response (CR+CRi+CRp) of 55%...
Saved in:
Published in: | Cancer research (Chicago, Ill.) Ill.), 2015-08, Vol.75 (15_Supplement), p.CT321-CT321 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c1001-2a6999b4a9c15fe572324b8816ceb5f662294a9d0e50572b2dcc1a81582e99e73 |
---|---|
cites | |
container_end_page | CT321 |
container_issue | 15_Supplement |
container_start_page | CT321 |
container_title | Cancer research (Chicago, Ill.) |
container_volume | 75 |
creator | Roboz, Gail Kantarjian, Hagop Kropf, Patricia Richie, Ellen Jain, Nitin Griffiths, Elizabeth Podoltsev, Nikola A. Walsh, Katherine O'Connell, Casey Stock, Wendy Rizzieri, David Tibes, Raoul Rosenblat, Todd Chung, Woonbok Taverna, Pietro Su, Xiang Yao Naim, Sue Azab, Mohammad Issa, Jean-Pierre |
description | Background: SGI-110 (guadecitabine) is a novel HMA that prolongs in vivo exposure of the active moiety decitabine following subcutaneous (SC) administration. We previously reported guadecitabine clinical activity in previously untreated elderly AML with Overall Complete Response (CR+CRi+CRp) of 55% using a standard 5-day regimen (Yee et al, 2014). Here we report the first results of a more intensive 10-day regimen in the same patient population.
Methods: Elderly AML patients (≥ 65y) with at least one of the following characteristics were enrolled: age ≥ 75y; poor Performance Status (PS) ≥ 2; significant comorbidities particularly cardiopulmonary dysfunction; poor risk cytogenetics; or secondary AML. Guadecitabine 60 mg/m2/d SC was administered for 10 days (Days 1-5; and 8-12) for the first 1-2 cycles followed by the 5-day regimen (Days 1-5) for subsequent cycles. Cycles were scheduled every 28 days. Primary endpoint was Overall Complete Response (Overall CR). Secondary endpoints included Overall Survival, Safety including all-cause 30-day and 60-day early mortality, and global maximum DNA demethylation from baseline by LINE-1 assay.
Results: Fifty two patients were treated with median age 77 (range 66-92) including 40 (77%) ≥75y; 34 (65%) male; 21 (40%) PS ≥ 2; 19 (36%) poor risk cytogenetics; and 13 (25%) secondary AML. The median bone marrow blasts percentage was 49% (range 16-98%). All patients had a minimum follow up of 3 months; 26 (50%) patients remain on treatment at the time of the analysis. Overall CR was observed in 24 patients (46%):14 CR (27%), 8 CRi (15%), and 2 CRp (4%). There was no significant difference between median DNA demethylation in responders (- 27%) and non-responders (-28%). Early all-cause 30-day and 60-day mortality occurred in 2 (4%) and 10 (19%) patients respectively. The most common Grade ≥3 Adverse Events considered by investigators to be drug-related were febrile neutropenia (33%), thrombocytopenia (27%), neutropenia (21%), anemia (15%), bacteremia (10%), and pneumonia (6%).
Conclusions: Administration of guadecitabine as a more intense 10-day regimen for the first 1-2 cycles was active with acceptable toxicity. However, and although it was not a randomized comparison, the 10-day regimen did not result in higher rate of Overall CR in previously untreated AML than what was previously reported for the 5-day regimen. A Phase III randomized clinical trial in previously untreated AML patients not considered candidates for intens |
doi_str_mv | 10.1158/1538-7445.AM2015-CT321 |
format | article |
fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1538_7445_AM2015_CT321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1158_1538_7445_AM2015_CT321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1001-2a6999b4a9c15fe572324b8816ceb5f662294a9d0e50572b2dcc1a81582e99e73</originalsourceid><addsrcrecordid>eNo9Uc1q4zAQFmULzbb7CsscE1i3kmw59t5M2CaFhB7ano0sjWMtjhQkpcXPuS9UpV16Gr6_GZiPkJ-M3jImqjsm8ipbFoW4bXacMpGtnnPOLsjsS_hGZpTSKhPFkl-R7yH8TVAwKmbkX9OF6KWK8JH6DffGhwgew2mMAVwPEhjNtJwStzcHtGfuaf2QMUZhvj9JjcpE2RmLi1_JHFA5q2GPFr2MxlkYpqM7YBymMWG7B5m0CPPNrlmAsXD0-GrcKYwTnGz0KCNqwFGjT0yz28Lb4EB6BOsiKGm10ckSoHc-xSPaYF4R1IAHF4d08zjdkMtejgF__J_X5OX-z_Nqk20f1w-rZpspRinLuCzruu4KWSsmehRLnvOiqypWKuxEX5ac10nUFAVNYse1UkxW6eUc6xqX-TUpP_cq70Lw2LdHbw7STy2j7bma9txAe26g_aym_Xhy_g4fU4PN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy</title><source>EZB Electronic Journals Library</source><creator>Roboz, Gail ; Kantarjian, Hagop ; Kropf, Patricia ; Richie, Ellen ; Jain, Nitin ; Griffiths, Elizabeth ; Podoltsev, Nikola A. ; Walsh, Katherine ; O'Connell, Casey ; Stock, Wendy ; Rizzieri, David ; Tibes, Raoul ; Rosenblat, Todd ; Chung, Woonbok ; Taverna, Pietro ; Su, Xiang Yao ; Naim, Sue ; Azab, Mohammad ; Issa, Jean-Pierre</creator><creatorcontrib>Roboz, Gail ; Kantarjian, Hagop ; Kropf, Patricia ; Richie, Ellen ; Jain, Nitin ; Griffiths, Elizabeth ; Podoltsev, Nikola A. ; Walsh, Katherine ; O'Connell, Casey ; Stock, Wendy ; Rizzieri, David ; Tibes, Raoul ; Rosenblat, Todd ; Chung, Woonbok ; Taverna, Pietro ; Su, Xiang Yao ; Naim, Sue ; Azab, Mohammad ; Issa, Jean-Pierre</creatorcontrib><description>Background: SGI-110 (guadecitabine) is a novel HMA that prolongs in vivo exposure of the active moiety decitabine following subcutaneous (SC) administration. We previously reported guadecitabine clinical activity in previously untreated elderly AML with Overall Complete Response (CR+CRi+CRp) of 55% using a standard 5-day regimen (Yee et al, 2014). Here we report the first results of a more intensive 10-day regimen in the same patient population.
Methods: Elderly AML patients (≥ 65y) with at least one of the following characteristics were enrolled: age ≥ 75y; poor Performance Status (PS) ≥ 2; significant comorbidities particularly cardiopulmonary dysfunction; poor risk cytogenetics; or secondary AML. Guadecitabine 60 mg/m2/d SC was administered for 10 days (Days 1-5; and 8-12) for the first 1-2 cycles followed by the 5-day regimen (Days 1-5) for subsequent cycles. Cycles were scheduled every 28 days. Primary endpoint was Overall Complete Response (Overall CR). Secondary endpoints included Overall Survival, Safety including all-cause 30-day and 60-day early mortality, and global maximum DNA demethylation from baseline by LINE-1 assay.
Results: Fifty two patients were treated with median age 77 (range 66-92) including 40 (77%) ≥75y; 34 (65%) male; 21 (40%) PS ≥ 2; 19 (36%) poor risk cytogenetics; and 13 (25%) secondary AML. The median bone marrow blasts percentage was 49% (range 16-98%). All patients had a minimum follow up of 3 months; 26 (50%) patients remain on treatment at the time of the analysis. Overall CR was observed in 24 patients (46%):14 CR (27%), 8 CRi (15%), and 2 CRp (4%). There was no significant difference between median DNA demethylation in responders (- 27%) and non-responders (-28%). Early all-cause 30-day and 60-day mortality occurred in 2 (4%) and 10 (19%) patients respectively. The most common Grade ≥3 Adverse Events considered by investigators to be drug-related were febrile neutropenia (33%), thrombocytopenia (27%), neutropenia (21%), anemia (15%), bacteremia (10%), and pneumonia (6%).
Conclusions: Administration of guadecitabine as a more intense 10-day regimen for the first 1-2 cycles was active with acceptable toxicity. However, and although it was not a randomized comparison, the 10-day regimen did not result in higher rate of Overall CR in previously untreated AML than what was previously reported for the 5-day regimen. A Phase III randomized clinical trial in previously untreated AML patients not considered candidates for intensive chemotherapy has been initiated with the 5-day regimen of guadecitabine.
Reference: Yee K, Daver N, Kropf P, et al: European Hematology Association Meeting, June 12-15, 2104; Milan, Italy. Abstract S647.
Citation Format: Gail Roboz, Hagop Kantarjian, Patricia Kropf, Ellen Richie, Nitin Jain, Elizabeth Griffiths, Nikola A. Podoltsev, Katherine Walsh, Casey O'Connell, Wendy Stock, David Rizzieri, Raoul Tibes, Todd Rosenblat, Woonbok Chung, Pietro Taverna, Xiang Yao Su, Sue Naim, Mohammad Azab, Jean-Pierre Issa. First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT321. doi:10.1158/1538-7445.AM2015-CT321</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2015-CT321</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT321-CT321</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1001-2a6999b4a9c15fe572324b8816ceb5f662294a9d0e50572b2dcc1a81582e99e73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Roboz, Gail</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Kropf, Patricia</creatorcontrib><creatorcontrib>Richie, Ellen</creatorcontrib><creatorcontrib>Jain, Nitin</creatorcontrib><creatorcontrib>Griffiths, Elizabeth</creatorcontrib><creatorcontrib>Podoltsev, Nikola A.</creatorcontrib><creatorcontrib>Walsh, Katherine</creatorcontrib><creatorcontrib>O'Connell, Casey</creatorcontrib><creatorcontrib>Stock, Wendy</creatorcontrib><creatorcontrib>Rizzieri, David</creatorcontrib><creatorcontrib>Tibes, Raoul</creatorcontrib><creatorcontrib>Rosenblat, Todd</creatorcontrib><creatorcontrib>Chung, Woonbok</creatorcontrib><creatorcontrib>Taverna, Pietro</creatorcontrib><creatorcontrib>Su, Xiang Yao</creatorcontrib><creatorcontrib>Naim, Sue</creatorcontrib><creatorcontrib>Azab, Mohammad</creatorcontrib><creatorcontrib>Issa, Jean-Pierre</creatorcontrib><title>Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy</title><title>Cancer research (Chicago, Ill.)</title><description>Background: SGI-110 (guadecitabine) is a novel HMA that prolongs in vivo exposure of the active moiety decitabine following subcutaneous (SC) administration. We previously reported guadecitabine clinical activity in previously untreated elderly AML with Overall Complete Response (CR+CRi+CRp) of 55% using a standard 5-day regimen (Yee et al, 2014). Here we report the first results of a more intensive 10-day regimen in the same patient population.
Methods: Elderly AML patients (≥ 65y) with at least one of the following characteristics were enrolled: age ≥ 75y; poor Performance Status (PS) ≥ 2; significant comorbidities particularly cardiopulmonary dysfunction; poor risk cytogenetics; or secondary AML. Guadecitabine 60 mg/m2/d SC was administered for 10 days (Days 1-5; and 8-12) for the first 1-2 cycles followed by the 5-day regimen (Days 1-5) for subsequent cycles. Cycles were scheduled every 28 days. Primary endpoint was Overall Complete Response (Overall CR). Secondary endpoints included Overall Survival, Safety including all-cause 30-day and 60-day early mortality, and global maximum DNA demethylation from baseline by LINE-1 assay.
Results: Fifty two patients were treated with median age 77 (range 66-92) including 40 (77%) ≥75y; 34 (65%) male; 21 (40%) PS ≥ 2; 19 (36%) poor risk cytogenetics; and 13 (25%) secondary AML. The median bone marrow blasts percentage was 49% (range 16-98%). All patients had a minimum follow up of 3 months; 26 (50%) patients remain on treatment at the time of the analysis. Overall CR was observed in 24 patients (46%):14 CR (27%), 8 CRi (15%), and 2 CRp (4%). There was no significant difference between median DNA demethylation in responders (- 27%) and non-responders (-28%). Early all-cause 30-day and 60-day mortality occurred in 2 (4%) and 10 (19%) patients respectively. The most common Grade ≥3 Adverse Events considered by investigators to be drug-related were febrile neutropenia (33%), thrombocytopenia (27%), neutropenia (21%), anemia (15%), bacteremia (10%), and pneumonia (6%).
Conclusions: Administration of guadecitabine as a more intense 10-day regimen for the first 1-2 cycles was active with acceptable toxicity. However, and although it was not a randomized comparison, the 10-day regimen did not result in higher rate of Overall CR in previously untreated AML than what was previously reported for the 5-day regimen. A Phase III randomized clinical trial in previously untreated AML patients not considered candidates for intensive chemotherapy has been initiated with the 5-day regimen of guadecitabine.
Reference: Yee K, Daver N, Kropf P, et al: European Hematology Association Meeting, June 12-15, 2104; Milan, Italy. Abstract S647.
Citation Format: Gail Roboz, Hagop Kantarjian, Patricia Kropf, Ellen Richie, Nitin Jain, Elizabeth Griffiths, Nikola A. Podoltsev, Katherine Walsh, Casey O'Connell, Wendy Stock, David Rizzieri, Raoul Tibes, Todd Rosenblat, Woonbok Chung, Pietro Taverna, Xiang Yao Su, Sue Naim, Mohammad Azab, Jean-Pierre Issa. First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT321. doi:10.1158/1538-7445.AM2015-CT321</description><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo9Uc1q4zAQFmULzbb7CsscE1i3kmw59t5M2CaFhB7ano0sjWMtjhQkpcXPuS9UpV16Gr6_GZiPkJ-M3jImqjsm8ipbFoW4bXacMpGtnnPOLsjsS_hGZpTSKhPFkl-R7yH8TVAwKmbkX9OF6KWK8JH6DffGhwgew2mMAVwPEhjNtJwStzcHtGfuaf2QMUZhvj9JjcpE2RmLi1_JHFA5q2GPFr2MxlkYpqM7YBymMWG7B5m0CPPNrlmAsXD0-GrcKYwTnGz0KCNqwFGjT0yz28Lb4EB6BOsiKGm10ckSoHc-xSPaYF4R1IAHF4d08zjdkMtejgF__J_X5OX-z_Nqk20f1w-rZpspRinLuCzruu4KWSsmehRLnvOiqypWKuxEX5ac10nUFAVNYse1UkxW6eUc6xqX-TUpP_cq70Lw2LdHbw7STy2j7bma9txAe26g_aym_Xhy_g4fU4PN</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Roboz, Gail</creator><creator>Kantarjian, Hagop</creator><creator>Kropf, Patricia</creator><creator>Richie, Ellen</creator><creator>Jain, Nitin</creator><creator>Griffiths, Elizabeth</creator><creator>Podoltsev, Nikola A.</creator><creator>Walsh, Katherine</creator><creator>O'Connell, Casey</creator><creator>Stock, Wendy</creator><creator>Rizzieri, David</creator><creator>Tibes, Raoul</creator><creator>Rosenblat, Todd</creator><creator>Chung, Woonbok</creator><creator>Taverna, Pietro</creator><creator>Su, Xiang Yao</creator><creator>Naim, Sue</creator><creator>Azab, Mohammad</creator><creator>Issa, Jean-Pierre</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20150801</creationdate><title>Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy</title><author>Roboz, Gail ; Kantarjian, Hagop ; Kropf, Patricia ; Richie, Ellen ; Jain, Nitin ; Griffiths, Elizabeth ; Podoltsev, Nikola A. ; Walsh, Katherine ; O'Connell, Casey ; Stock, Wendy ; Rizzieri, David ; Tibes, Raoul ; Rosenblat, Todd ; Chung, Woonbok ; Taverna, Pietro ; Su, Xiang Yao ; Naim, Sue ; Azab, Mohammad ; Issa, Jean-Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1001-2a6999b4a9c15fe572324b8816ceb5f662294a9d0e50572b2dcc1a81582e99e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roboz, Gail</creatorcontrib><creatorcontrib>Kantarjian, Hagop</creatorcontrib><creatorcontrib>Kropf, Patricia</creatorcontrib><creatorcontrib>Richie, Ellen</creatorcontrib><creatorcontrib>Jain, Nitin</creatorcontrib><creatorcontrib>Griffiths, Elizabeth</creatorcontrib><creatorcontrib>Podoltsev, Nikola A.</creatorcontrib><creatorcontrib>Walsh, Katherine</creatorcontrib><creatorcontrib>O'Connell, Casey</creatorcontrib><creatorcontrib>Stock, Wendy</creatorcontrib><creatorcontrib>Rizzieri, David</creatorcontrib><creatorcontrib>Tibes, Raoul</creatorcontrib><creatorcontrib>Rosenblat, Todd</creatorcontrib><creatorcontrib>Chung, Woonbok</creatorcontrib><creatorcontrib>Taverna, Pietro</creatorcontrib><creatorcontrib>Su, Xiang Yao</creatorcontrib><creatorcontrib>Naim, Sue</creatorcontrib><creatorcontrib>Azab, Mohammad</creatorcontrib><creatorcontrib>Issa, Jean-Pierre</creatorcontrib><collection>CrossRef</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roboz, Gail</au><au>Kantarjian, Hagop</au><au>Kropf, Patricia</au><au>Richie, Ellen</au><au>Jain, Nitin</au><au>Griffiths, Elizabeth</au><au>Podoltsev, Nikola A.</au><au>Walsh, Katherine</au><au>O'Connell, Casey</au><au>Stock, Wendy</au><au>Rizzieri, David</au><au>Tibes, Raoul</au><au>Rosenblat, Todd</au><au>Chung, Woonbok</au><au>Taverna, Pietro</au><au>Su, Xiang Yao</au><au>Naim, Sue</au><au>Azab, Mohammad</au><au>Issa, Jean-Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2015-08-01</date><risdate>2015</risdate><volume>75</volume><issue>15_Supplement</issue><spage>CT321</spage><epage>CT321</epage><pages>CT321-CT321</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><abstract>Background: SGI-110 (guadecitabine) is a novel HMA that prolongs in vivo exposure of the active moiety decitabine following subcutaneous (SC) administration. We previously reported guadecitabine clinical activity in previously untreated elderly AML with Overall Complete Response (CR+CRi+CRp) of 55% using a standard 5-day regimen (Yee et al, 2014). Here we report the first results of a more intensive 10-day regimen in the same patient population.
Methods: Elderly AML patients (≥ 65y) with at least one of the following characteristics were enrolled: age ≥ 75y; poor Performance Status (PS) ≥ 2; significant comorbidities particularly cardiopulmonary dysfunction; poor risk cytogenetics; or secondary AML. Guadecitabine 60 mg/m2/d SC was administered for 10 days (Days 1-5; and 8-12) for the first 1-2 cycles followed by the 5-day regimen (Days 1-5) for subsequent cycles. Cycles were scheduled every 28 days. Primary endpoint was Overall Complete Response (Overall CR). Secondary endpoints included Overall Survival, Safety including all-cause 30-day and 60-day early mortality, and global maximum DNA demethylation from baseline by LINE-1 assay.
Results: Fifty two patients were treated with median age 77 (range 66-92) including 40 (77%) ≥75y; 34 (65%) male; 21 (40%) PS ≥ 2; 19 (36%) poor risk cytogenetics; and 13 (25%) secondary AML. The median bone marrow blasts percentage was 49% (range 16-98%). All patients had a minimum follow up of 3 months; 26 (50%) patients remain on treatment at the time of the analysis. Overall CR was observed in 24 patients (46%):14 CR (27%), 8 CRi (15%), and 2 CRp (4%). There was no significant difference between median DNA demethylation in responders (- 27%) and non-responders (-28%). Early all-cause 30-day and 60-day mortality occurred in 2 (4%) and 10 (19%) patients respectively. The most common Grade ≥3 Adverse Events considered by investigators to be drug-related were febrile neutropenia (33%), thrombocytopenia (27%), neutropenia (21%), anemia (15%), bacteremia (10%), and pneumonia (6%).
Conclusions: Administration of guadecitabine as a more intense 10-day regimen for the first 1-2 cycles was active with acceptable toxicity. However, and although it was not a randomized comparison, the 10-day regimen did not result in higher rate of Overall CR in previously untreated AML than what was previously reported for the 5-day regimen. A Phase III randomized clinical trial in previously untreated AML patients not considered candidates for intensive chemotherapy has been initiated with the 5-day regimen of guadecitabine.
Reference: Yee K, Daver N, Kropf P, et al: European Hematology Association Meeting, June 12-15, 2104; Milan, Italy. Abstract S647.
Citation Format: Gail Roboz, Hagop Kantarjian, Patricia Kropf, Ellen Richie, Nitin Jain, Elizabeth Griffiths, Nikola A. Podoltsev, Katherine Walsh, Casey O'Connell, Wendy Stock, David Rizzieri, Raoul Tibes, Todd Rosenblat, Woonbok Chung, Pietro Taverna, Xiang Yao Su, Sue Naim, Mohammad Azab, Jean-Pierre Issa. First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT321. doi:10.1158/1538-7445.AM2015-CT321</abstract><doi>10.1158/1538-7445.AM2015-CT321</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-5472 |
ispartof | Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT321-CT321 |
issn | 0008-5472 1538-7445 |
language | eng |
recordid | cdi_crossref_primary_10_1158_1538_7445_AM2015_CT321 |
source | EZB Electronic Journals Library |
title | Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not candidates for intensive chemotherapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A50%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%20CT321:%20First%20results%20of%20a%2010-day%20regimen%20of%20SGI-110%20(guadecitabine),%20a%20second%20generation%20hypomethylating%20agent%20(HMA)%20in%20previously%20untreated%20elderly%20AML%20who%20are%20not%20candidates%20for%20intensive%20chemotherapy&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Roboz,%20Gail&rft.date=2015-08-01&rft.volume=75&rft.issue=15_Supplement&rft.spage=CT321&rft.epage=CT321&rft.pages=CT321-CT321&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2015-CT321&rft_dat=%3Ccrossref%3E10_1158_1538_7445_AM2015_CT321%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1001-2a6999b4a9c15fe572324b8816ceb5f662294a9d0e50572b2dcc1a81582e99e73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |